scholarly journals High-dose-rate brachytherapy boost for locally advanced cervical cancer: Oncological outcome and toxicity analysis of 4 fractionation schemes

2021 ◽  
Author(s):  
Maud le Guyader ◽  
Daniel Lam Cham Kee ◽  
Brice Thamphya ◽  
Renaud Schiappa ◽  
Mathieu Gautier ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Dose Rate ◽  
Locally Advanced ◽  
Oncological Outcome ◽  
High Dose Rate ◽  
High Dose ◽  
Advanced Cervical Cancer ◽  
Locally Advanced Cervical Cancer ◽  
Brachytherapy Boost ◽  
Toxicity Analysis

scholarly journals Concomitant cervical and transperineal parametrial high-dose-rate brachytherapy boost for locally advanced cervical cancer

2016 ◽  
Vol 1 ◽  
pp. 23-31 ◽  
Author(s):  
Caroline Bailleux ◽  
Alexander Tuan Falk ◽  
Marie-Eve Chand-Fouche ◽  
Mathieu Gautier ◽  
Emmanuel Barranger ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Dose Rate ◽  
Locally Advanced ◽  
High Dose Rate ◽  
High Dose ◽  
Advanced Cervical Cancer ◽  
High Dose Rate Brachytherapy ◽  
Locally Advanced Cervical Cancer ◽  
Brachytherapy Boost

scholarly journals Does initial 45Gy of pelvic intensity-modulated radiotherapy reduce late complications in patients with locally advanced cervical cancer? A cohort control study using definitive chemoradiotherapy with high-dose rate brachytherapy

2013 ◽  
Vol 47 (2) ◽  
pp. 176-184 ◽  
Author(s):  
Shang-Wen Chen ◽  
Ji-An Liang ◽  
Lian-Shung Yeh ◽  
Wei-Chun Chang ◽  
Wu-Chou Lin ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Dose Rate ◽  
Cancer Patients ◽  
Locally Advanced ◽  
High Dose Rate ◽  
High Dose ◽  
Advanced Cervical Cancer ◽  
Similar Treatment ◽  
Locally Advanced Cervical Cancer ◽  
Intensity Modulated

Background. Comparing initial 45 Gy of pelvic intensity-modulated radiation therapy (IMRT) and non-IMRT in terms of the late toxicities associated with advanced cervical cancer that has also been treated with definitive concurrent chemoradiotherapy and high-dose rate intracavitary brachytherapy (HDRICB). Patients and methods. This retrospective study included 320 stage IB2-IIIB cervical cancer patients treated with CCRT (83 IMRT and 237 non-IMRT). The two groups had similar stage and HDRICB ratings. Following 45 Gy to the pelvis, HDRICB of 24 Gy in four courses was prescribed. Late toxicities, including rectal complications (RC), bladder complications (BC) and non-rectal intestinal injury (NRRII), were scored by the Common Terminology Criteria for Adverse Events. A logistic regression was used to estimate the odds ratio (OR) of the complications. Results. With a median follow-up duration of 33 and 77 months for IMRT and non-IMRT, 33 patients had Grade 2 or higher late RC (7.2% IMRT, 11.4% non-IMRT), whereas that for BC was 40 (9.6% IMRT, 13.5% non-IMRT) and for NRRII was 48 (12.0% IMRT, 16.0% non-IMRT). The cumulative rate for total grade 3 or higher gastrointestinal or genitourinary toxicities was 8.4% and 11.8% (p = 0.33). IMRT did not reduce the OR for all endpoints; however, the ORs for rectum and bladder reference doses to Point A were associated with RC and BC. Conclusions. Locally advanced cervical cancer patients treated with initial 45Gy of pelvic IMRT and HDRICB have similar treatment-related late toxicities as those treated with non-IMRT. Optimization of the brachytherapy scheme is essential to minimize late toxicities.

Sign in / Sign up

Export Citation Format

Share Document